PerkinElmer, Inc. (NYSE:PKI) Insider Sells $175,322.56 in Stock

PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 2,324 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $75.44, for a total transaction of $175,322.56. Following the transaction, the insider now owns 8,876 shares of the company’s stock, valued at approximately $669,605.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Andrew Okun also recently made the following trade(s):

  • On Monday, February 5th, Andrew Okun sold 2,273 shares of PerkinElmer stock. The stock was sold at an average price of $77.86, for a total transaction of $176,975.78.
  • On Friday, December 15th, Andrew Okun sold 12,680 shares of PerkinElmer stock. The stock was sold at an average price of $72.00, for a total transaction of $912,960.00.

PerkinElmer, Inc. (NYSE:PKI) opened at $76.39 on Monday. The firm has a market capitalization of $8,420.10, a price-to-earnings ratio of 28.94, a PEG ratio of 1.76 and a beta of 0.76. The company has a current ratio of 1.27, a quick ratio of 0.90 and a debt-to-equity ratio of 0.72. PerkinElmer, Inc. has a twelve month low of $53.97 and a twelve month high of $84.49.

PerkinElmer (NYSE:PKI) last announced its earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.94 by $0.03. PerkinElmer had a return on equity of 13.30% and a net margin of 12.97%. The company had revenue of $641.63 million for the quarter, compared to analyst estimates of $619.14 million. During the same period in the prior year, the company posted $0.83 EPS. The firm’s quarterly revenue was up 13.2% compared to the same quarter last year. sell-side analysts anticipate that PerkinElmer, Inc. will post 3.52 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 10th. Stockholders of record on Friday, April 13th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.37%. The ex-dividend date is Thursday, April 12th. PerkinElmer’s dividend payout ratio is presently 10.61%.

PKI has been the subject of several research analyst reports. Bank of America upgraded shares of PerkinElmer from an “underperform” rating to a “neutral” rating and set a $78.00 price objective for the company in a research note on Tuesday, December 19th. Barclays boosted their price objective on PerkinElmer from $69.00 to $73.00 and gave the company an “underweight” rating in a research note on Friday, January 26th. ValuEngine cut PerkinElmer from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research raised PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a research note on Monday, January 8th. Finally, Robert W. Baird increased their price objective on PerkinElmer from $75.00 to $78.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the stock. PerkinElmer currently has a consensus rating of “Hold” and an average target price of $76.85.

Several hedge funds have recently made changes to their positions in PKI. Balyasny Asset Management LLC purchased a new stake in shares of PerkinElmer in the second quarter worth about $271,000. Cornerstone Capital Management Holdings LLC. boosted its position in PerkinElmer by 37.5% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 25,886 shares of the medical research company’s stock worth $1,763,000 after purchasing an additional 7,053 shares in the last quarter. BlueCrest Capital Management Ltd purchased a new position in PerkinElmer during the second quarter worth approximately $440,000. Cubist Systematic Strategies LLC purchased a new position in shares of PerkinElmer in the second quarter valued at approximately $269,000. Finally, Nomura Holdings Inc. purchased a new position in shares of PerkinElmer in the second quarter valued at approximately $567,000. 90.06% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “PerkinElmer, Inc. (NYSE:PKI) Insider Sells $175,322.56 in Stock” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/19/perkinelmer-inc-pki-insider-sells-175322-56-in-stock.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply